Imatinib mesylate causes hypopigmentation in the skin

Leong, Kin Wah; Lee, Thoong Chow; Goh, Ai Sim

doi:10.1002/cncr.20267

Cited by 30 publications

(23 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathogenesis might be through the crossinhibition of c-Kit tyrosine receptor kinase, which is required for normal melanosome development in epidermal melanocytes [18,19]. This phenomenon was observed in 90 of our patient cohort (77.6%), which is comparable with the previous report that 65% of 20 Malay patients experienced skin hypopigmentation [20]. However, it is seldom seen in Western patients.…”

Section: Discussionsupporting

confidence: 90%

Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population

et al. 2009

View full text Add to dashboard Cite

There is limited data from developing countries on the current status of imatinib treatment for chronic myeloid leukemia (CML), thus we retrospectively analyzed 116 Chinese CML patients who received imatinib between 2003 and 2008. The response rates for 102 patients in chronic phase were: complete hematologic, 94.1%; complete cytogenetic, 69.6%; and complete molecular response, 54.9%. For 14 patients in the accelerated phase, the respective response rates were 85.7, 35.7 and 28.6%. The 3-year progression-free survival and 5-year overall survival were 73.3 and 74.8%. Although skin hypopigmentation occurs as the most common side effect (77.6%), imatinib is still well tolerated. In addition to the known pretreatment characteristics of spleen size, leukocyte and platelet counts, disease phase and Sokal scores, we found that delayed therapy, variant Philadelphia chromosome translocations and IM-related grade 3/4 leucopenia were associated with an inferior cytogenetic response. Four factors emerged as predictors of disease progression: molecular response, cytogenetic response, disease phase and disease duration prior to imatinib treatment, but only the latter three remained significant after multivariate analysis. The results indicate that the suboptimal outcome in Chinese patients is associated with delayed imatinib therapy, so the importance of the optimal treatment opportunity for CML should be emphasized.

show abstract

Section: Discussionsupporting

confidence: 90%

Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population

et al. 2009

View full text Add to dashboard Cite

show abstract

“…30,31 Hypopigmentation has been reported in 18% to 40.9% of patients with CML receiving imatinib mesylate. [32][33][34][35][36][37][38][39][40][41][42] An explorative colorimetric study demonstrated that imatinib mesylate significantly lightens unexposed skin. 41 Imatinib mesylatee induced depigmentation is not specific to ethnic background, yet skin lightening is more evident among patients with darker skin.…”

Section: Discussionmentioning

confidence: 99%

Imatinib mesylate–induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors

Han

Wang

2008

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…An additional 13 patients of Asian descent developed gradual skin depigmentation. 88 One patient in this series reported an inability to tan despite hours of sun exposure, and another reported increased pigmentation upon discontinuing imatinib therapy and decreased pigmentation upon reintroduction. Five lighter-skinned individuals noticed photosensitivity and inability to tan on imatinib, and patchy depigmentation was seen in 1 of these patients.…”

Section: Multikinase Inhibitorsmentioning

confidence: 96%